The HINT3 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from Jurkat T lymphocytes, with targeted disruption of the HINT3 gene. This heterogeneous pool enables loss-of-function studies of histidine triad nucleotide-binding protein 3 in a human T-cell context. The polyclonal format preserves endogenous regulatory networks while abolishing gene function, suitable for investigating mitochondrial metabolism and apoptosis.
The Jurkat clone E6-1 host cells are an immortalized T lymphocyte line from a patient with acute T cell leukemia, widely used for studying T cell receptor signaling, apoptosis, and immune responses. These cells exhibit well-defined apoptotic pathways and consistent growth, providing a reproducible model for functional genomics. Their transformed phenotype recapitulates key features of T-cell leukemia, including dysregulated proliferation.
HINT3 encodes a mitochondrial nucleotide phosphoramidase that hydrolyzes phosphoramidate bonds, regulating adenosine monophosphate (AMP) and guanosine monophosphate (GMP) pools. It is regulated by oxidative stress, TFAM, PGC-1??, and ATP levels, and interacts with Tom20, mitochondrial processing peptidase, HSPA9, and adenine nucleotide translocator. HINT3 modulates mitochondrial membrane potential and cytochrome c release, controlling caspase-9 and caspase-3 activation. BCL2 family members BAX and BCL2, ROS, and p53 are key pathway components. HINT3 disruption impairs phosphoramidase activity, alters nucleotide pools, disrupts oxidative phosphorylation, and sensitizes cells to apoptosis by promoting mitochondrial membrane permeabilization and cytochrome c release.
In Jurkat cells, HINT3 knockout aids in dissecting the interplay between mitochondrial metabolism and apoptosis regulation. T-ALL cells often display mitochondrial dysfunction and redox imbalance; HINT3 loss uncovers vulnerabilities to apoptotic induction. This model is valuable for studying purine nucleotide metabolism, mitochondrial stress, and ROS signaling, and for evaluating therapeutic strategies against T-cell leukemia.
Applications include flow cytometry for apoptosis (Annexin V/PI), JC-1 mitochondrial membrane potential assays, ATP measurements, and western blotting for caspase-3 and cytochrome c. RT-qPCR for BCL2 family genes, drug sensitivity screens (etoposide, doxorubicin), DCFDA ROS detection, and co-immunoprecipitation of HINT3 interactions are also facilitated. For more details, contact Ascent Research.
